Cargando…
Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis
Interleukin 1 (IL-1) has been indicated as a mediator of recurrent pericarditis. Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing interleukin 1 alpha (IL-1α) and interleukin 1 beta (IL-1β), has demonstrated promising results in a phase II study in recurrent or refractory peri...
Autores principales: | Affas, Ziad R, Rasool, Banan Q, Sebastian, Sneha A, Affas, Rafe S, Mohamadtahr, Sayran K, Saoor, Nagham H, Mohammad, Aya N, Saoor, Ghada H, Husain, Bzhar A, Touza, Rowaid, Touza, Ghaid, Amen, Shwan, Nazzaro, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730293/ https://www.ncbi.nlm.nih.gov/pubmed/36505131 http://dx.doi.org/10.7759/cureus.31226 |
Ejemplares similares
-
A Meta-Analysis Comparing Venoarterial (VA) Extracorporeal Membrane Oxygenation (ECMO) to Impella for Acute Right Ventricle Failure
por: Affas, Ziad R, et al.
Publicado: (2021) -
Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022) -
Correction to: Rilonacept (Interleukin‑1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022) -
Continuous positive airway pressure reduces the incidence of atrial fibrillation in patients with obstructive sleep apnea: A Meta-Analysis and Systematic Review
por: Affas, Ziad, et al.
Publicado: (2022) -
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
por: Brucato, Antonio, et al.
Publicado: (2023)